StromaForte
/ Cellcolabs
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
April 22, 2026
An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis
(clinicaltrials.gov)
- P2/3 | N=140 | Recruiting | Sponsor: Cellcolabs Clinical SPV Limited
New P2/3 trial • Immunology • Osteoarthritis • Pain • Rheumatology
April 17, 2026
A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients
(clinicaltrials.gov)
- P1/2 | N=12 | Completed | Sponsor: Cellcolabs Clinical SPV Limited | Trial completion date: Apr 2025 ➔ Aug 2025 | Trial primary completion date: Nov 2024 ➔ Aug 2025 | Recruiting ➔ Completed
Trial completion • Trial completion date • Trial primary completion date • TNFA
April 17, 2026
A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis
(clinicaltrials.gov)
- P1/2 | N=12 | Completed | Sponsor: Cellcolabs Clinical SPV Limited | Recruiting ➔ Completed
Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology
March 26, 2026
2024-001-SWE: Long Term Effects of Comparative Types of MSC Treatments.
(clinicaltrialsregister.eu)
- P3/4 | N=200 | Completed | Sponsor: Cellcolabs AB | Not yet recruiting ➔ Completed
Biomarker • Trial completion
April 19, 2024
A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Cellcolabs Clinical LTD. | N=12 ➔ 30 | Trial completion date: Sep 2024 ➔ Oct 2028 | Trial primary completion date: May 2024 ➔ Oct 2027
Enrollment change • Stroma • Trial completion date • Trial primary completion date • Musculoskeletal Diseases
April 19, 2024
A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular Events
(clinicaltrials.gov)
- P1/2 | N=100 | Recruiting | Sponsor: Cellcolabs Clinical LTD. | N=30 ➔ 100 | Trial completion date: Jul 2024 ➔ Oct 2029 | Trial primary completion date: Apr 2024 ➔ Oct 2029
Enrollment change • Stroma • Trial completion date • Trial primary completion date • Cardiovascular • IL6 • TNFA
April 18, 2024
A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Cellcolabs Clinical LTD. | Trial completion date: Jan 2025 ➔ Jan 2027 | Initiation date: Oct 2023 ➔ Jan 2025 | Trial primary completion date: Oct 2024 ➔ Jan 2026
Stroma • Trial completion date • Trial initiation date • Trial primary completion date • TNFA
November 22, 2023
A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: Cellcolabs Clinical SPV Limited | Trial completion date: Apr 2024 ➔ Apr 2025
Trial completion date • TNFA
October 18, 2023
A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular Events
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Cellcolabs Clinical LTD.
New P1/2 trial • Stroma • Cardiovascular
October 16, 2023
A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: Cellcolabs Clinical SPV Limited
New P1/2 trial • Stroma • Immunology • Osteoarthritis • Pain • Rheumatology • IL6 • TNFA
1 to 10
Of
10
Go to page
1